Your browser doesn't support javascript.
loading
Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis.
Hildenbrand, Florian F; Illi, Barbara; von Felten, Stefanie; Bachofner, Jacqueline; Gawinecka, Joanna; von Eckardstein, Arnold; Müllhaupt, Beat; Mertens, Joachim C; Blümel, Sena.
Afiliación
  • Hildenbrand FF; Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Illi B; Division of Gastroenterology and Hepatology, Stadtspital Zurich, Zurich, Switzerland.
  • von Felten S; Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Bachofner J; Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
  • Gawinecka J; Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • von Eckardstein A; Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Müllhaupt B; Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Mertens JC; Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Blümel S; Center of Gastroenterology, Klinik Hirslanden, Zurich, Switzerland.
BMC Gastroenterol ; 24(1): 54, 2024 Jan 30.
Article en En | MEDLINE | ID: mdl-38291388
ABSTRACT
BACKGROUND &

AIMS:

With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a serum biomarker for fibrotic processes. The aim of this study was to evaluate sST2 as marker for liver fibrosis in patients successfully treated for chronic hepatitis C.

METHODS:

424 patients from the Swiss Hepatitis C Cohort Study were screened for inclusion in this post-hoc cohort study. Inclusion criteria were sustained virological response (SVR), available elastography (VCTE) and serum samples for biomarker analysis before and after treatment. For the validation of sST2, values were compared to VCTE, FIB-4 and APRI using Spearman's correlation and AUROC analyses.

RESULTS:

Data of 164 subjects were finally analyzed. Median sST2 values slightly increased with VCTE-derived fibrosis stages and remained stable after reaching SVR within the respective fibrosis stage, suggesting that sST2 is not influenced by liver inflammation. However, correlation of sST2 pre- and post-treatment with VCTE was fair (Spearman's rho = 0.39 and rho = 0.36). The area under the curve (AUROC) for sST2 in detecting VCTE-defined F4 fibrosis (vs. F0-F3) before therapy was 0.74 (95%CI 0.65-0.83), and 0.67(95%CI 0.56-0.78) for the discrimination of F3/F4 fibrosis vs. F0-F2. Adding sST2 to either APRI or FIB-4, respectively, increased diagnostic performance of both tests.

CONCLUSIONS:

sST2 can potentially identify patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatitis C Crónica / Diagnóstico por Imagen de Elasticidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatitis C Crónica / Diagnóstico por Imagen de Elasticidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article